A recent study published in The Lancet has concluded that medicinal cannabis is not effective in treating mental health conditions such as anxiety, depression, and post-traumatic stress disorder (PTSD). This analysis is noted as the largest of its kind, encompassing data from 54 randomized controlled trials conducted over 45 years. The findings emerge amidst rising medicinal cannabis use, with approximately 27% of individuals aged 16-65 in the U.S. and Canada reporting its use for medical purposes, often to manage mental health symptoms.
Lead author Dr. Jack Wilson from the University of Sydney's Matilda Centre highlighted concerns regarding the implications of these findings on the approval of medicinal cannabis for mental health disorders. He suggested that the routine use of medicinal cannabis could potentially exacerbate mental health issues, increasing the risk of psychotic symptoms and delaying access to more effective treatments.
While the study identified limited potential benefits of medicinal cannabis for conditions such as cannabis use disorder, autism, insomnia, and Tourette's syndrome, Dr. Wilson cautioned that the evidence supporting these uses remains weak. The research did indicate that medicinal cannabis might be effective in certain medical contexts, such as reducing seizures in epilepsy or alleviating pain, but underscored that its efficacy for mental health disorders is insufficient.
The review also examined the impact of medicinal cannabis on substance use disorders, revealing mixed results. It suggested that cannabis-based treatments could assist those with cannabis dependence but may worsen cravings in individuals with cocaine use disorder.
Experts, including those from the American Medical Association, have called for stronger regulation of medicinal cannabis, emphasizing the need for more robust evidence to guide clinical decisions and ensure patient safety.